{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:02:26Z","timestamp":1791212546108,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T00:00:00Z","timestamp":1378080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T00:00:00Z","timestamp":1378080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1002\/pbc.24721","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T15:07:02Z","timestamp":1378134422000},"page":"369-372","source":"Crossref","is-referenced-by-count":55,"title":["Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"61","author":[{"given":"Michael","family":"Rytting","sequence":"first","affiliation":[{"name":"Department of Pediatrics; The University of Texas MD Anderson Cancer Center; Texas"},{"name":"Department of Leukemia; The University of Texas MD Anderson Cancer Center; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Triche","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; The University of Texas MD Anderson Cancer Center; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Leukemia; The University of Texas MD Anderson Cancer Center; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia; The University of Texas MD Anderson Cancer Center; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia; The University of Texas MD Anderson Cancer Center; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"10.1002\/pbc.24721-BIB0001|pbc24721-cit-0001","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1365-2141.2003.04584.x","article-title":"Long-term follow-up of relapsed childhood acute lymphoblastic leukaema","volume":"123","author":"Chessells","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1002\/pbc.24721-BIB0002|pbc24721-cit-0002","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.1995.13.2.352","article-title":"Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association","volume":"13","author":"Uderzo","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24721-BIB0003|pbc24721-cit-0003","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.24721-BIB0004|pbc24721-cit-0004","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24721-BIB0005|pbc24721-cit-0005","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24721-BIB0006|pbc24721-cit-0006","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V101.10.3835","article-title":"Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis","volume":"101","author":"Borgmann","year":"2003","journal-title":"Blood"},{"key":"10.1002\/pbc.24721-BIB0007|pbc24721-cit-0007","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1002\/pbc.24721-BIB0008|pbc24721-cit-0008","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1002\/pbc.24721-BIB0009|pbc24721-cit-0009","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"10.1002\/pbc.24721-BIB0010|pbc24721-cit-0010","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V71.5.1480.1480","article-title":"Expression and structure of CD22 in acute leukemia","volume":"71","author":"Boue","year":"1988","journal-title":"Blood"},{"key":"10.1002\/pbc.24721-BIB0011|pbc24721-cit-0011","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24721-BIB0012|pbc24721-cit-0012","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/chir.20990","article-title":"Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma 1I","volume":"23","author":"Ellestad","year":"2011","journal-title":"Chirality"},{"key":"10.1002\/pbc.24721-BIB0013|pbc24721-cit-0013","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1002\/pbc.24721-BIB0014|pbc24721-cit-0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.24721-BIB0015|pbc24721-cit-0015","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1002\/pbc.24721-BIB0016|pbc24721-cit-0016","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1002\/pbc.24721-BIB0017|pbc24721-cit-0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","article-title":"The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells","volume":"26","author":"de Vries","year":"2012","journal-title":"Leukemia"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24721","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24721","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.24721\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:20:33Z","timestamp":1596104433000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pbc.24721"}},"subtitle":["Phase 2 Study of CMC-544"],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24721","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,2]]}}}